- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | CARsgen Therapeutics Announces 2026 Interim Results | 210 | PR Newswire | SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 18.08. | CARSGEN-B (02171): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 07.08. | CARSGEN-B CT1190B Receives NMPA IND Approval for Treatment of Relapsed/Refractory Large B-Cell Lymphoma | 1 | AASTOCKS | ||
| 07.08. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - CT1190B RECEIVED IND CLEARANCE FROM THE NMPA FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R ... | 1 | HKEx | ||
| 06.08. | CARSGEN-B (02171): DATE OF BOARD MEETING | 2 | HKEx | ||
| 04.08. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - CT0596 RECEIVED IND CLEARANCE FROM THE NMPA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE ... | 3 | HKEx | ||
| 17.07. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 15.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL ACCEPTED FOR POSTER PRESENTATION AT ESMO CONGRESS 2026 | 1 | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.07. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 1 | HKEx | ||
| 24.06. | China's CARsgen Slides for Second Day on Hefty Price Tag for World's First Solid Tumor CAR-T Therapy | 3 | Yicai Global | ||
| 22.06. | CARsgen makes history as China approves world's first CAR-T therapy for solid tumors | 1 | FiercePharma | ||
| 22.06. | CARSgen bags world-first approval for solid tumour CAR-T | 2 | pharmaphorum | ||
| 22.06. | CARsgen's Solid-Tumor CAR-T Therapy Nears China Approval, a Global First | 1 | Yicai Global | ||
| 22.06. | CARSGEN-B (02171): INSIDE INFORMATION ANNOUNCEMENT - THE NMPA APPROVES THE NEW DRUG APPLICATION FOR THE CLAUDIN18.2 CAR T-CELL THERAPY PRODUCT SATRICABTAGENE ... | 1 | HKEx | ||
| 15.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AND CT1190B AT 2026 EHA ANNUAL CONGRESS | 1 | HKEx | ||
| 01.06. | CARsgen Therapeutics: Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting | 110 | PR Newswire | SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 01.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON SATRI-CEL AT THE 2026 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 26.05. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.05. | CARSGEN-B (02171): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 4 | HKEx |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.